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The endocrine system and particular endocrine organs, including the thyroid, undergo important functional
changes during aging. The prevalence of thyroid disorders increases with age and numerous morphological and
physiological changes of the thyroid gland during the process of aging are well-known. It is to be stressed that the
clinical course of thyroid diseases in the elderly differs essentially from that observed in younger individuals,
because symptoms are more subtle and are often attributed to normal aging. Subclinical hypo- and
hyperthyroidism, as well as thyroid neoplasms, require special attention in elderly subjects. Intriguingly, decreased
thyroid function, as well as thyrotropin (TSH) levels – progressively shifting to higher values with age – may
contribute to the increased lifespan.
This short review focuses on recent findings concerning the alterations in thyroid function during aging, including
these which may potentially lead to extended longevity, both in humans and animals.
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The endocrine system and particular endocrine organs,
including the thyroid gland, undergo – similarly to other
organ systems – crucial functional changes with aging.
Numerous morphological and physiological changes of
the thyroid during the process of aging are well-known
[1-3]. A specificity of thyroid diseases in the elderly, dif-
fering essentially from that observed in younger subjects,
relies on the presence of more subtle symptoms which
are often attributed to normal aging. Therefore, subclin-
ical hypo- and hyperthyroidism, as well as thyroid neo-
plasms, the prevalence of which increases with age,
require special attention in elderly subjects. Interestingly,
altered thyroid function may contribute to the extended
longevity. The present review focuses on the newest
findings concerning the alterations in thyroid function
during the process of aging.Thyroid dysfunction with aging
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are more frequent than overt diseases in general popula-
tion, as well as in elderly people [4,5]. Consistently, the
prevalence of subclinical hypothyroidism, which is char-
acterized by normal free thyroxine (FT4) and elevated
thyrotropin (TSH) levels, increases with aging [6-12]
and ranges from 3 to 16% in individuals aged 60 years
and older [13].
Although it is known that overt thyroid disorders
negatively affect physical and cognitive function in eld-
erly people – for example, overt hypothyroidism is asso-
ciated with the impairment of attention, concentration,
memory, perceptual functions, language, and executive
functions [14], subclinical hypothyroidism is not asso-
ciated with impairment of physical and cognitive func-
tion or depression in individuals aged 65 years and older,
as compared to euthyroidism [15]. Also Park et al. [16]
have demonstrated that subclinical hypothyroidism in
elderly subjects is neither associated with cognitive im-
pairment, depression, poor quality of life nor with meta-
bolic disturbances. On the other hand, other studies
demonstrated the presence of – at least – mild cognitive
impairment in people with subclinical hypothyroidism at
mean age under 65 years (reviewed in [17]). Further-
more, as reported by de Jongh et al. [15], subclinicalLtd. This is an Open Access article distributed under the terms of the Creative
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increased overall mortality risk. Similar findings were
shown by Rodondi et al. [18] who analyzed data from
numerous large prospective cohorts and demonstrated
that total mortality was not increased in subjects with
subclinical hypothyroidism, although the risk of coron-
ary heart disease (CHD) events and of CHD mortality
increased with TSH levels 10 mIU/l or higher. Neverthe-
less, it should be emphasized that this analysis regarded
numerous different populations (cohorts) which con-
sisted of not only elderly people and that the effect in
question, i.e. of increasing TSH level on CHD incidents
was not influenced by age [18].
Undoubtedly, there are obvious indications for treat-
ment of overt hypothyroidism. On the other hand, indi-
cations for treatment of subclinical hypothyroidism are
still controversial. Despite improvement of lipid profile
due to treatment of subclinical hypothyroidism, there is
no clear evidence that this beneficial effect can be asso-
ciated with decreased cardiovascular or all-cause mortal-
ity in elderly patients [19]. Furthermore, Parle et al. [20]
have reported that L-thyroxine replacement therapy does
not improve cognitive function in elderly individuals
with subclinical hypothyroidism. When the natural his-
tory of subclinical hypothyroidism was evaluated in the
elderly, the final results depended on the presence or ab-
sence of thyroid antibodies and on that to what extent
TSH concentration was increased. Thus, a quite high
rate of reversion of subclinical hypothyroidism to eu-
thyroid status in adults aged at least 65 years with lower
baseline TSH levels and antithyroid peroxidase antibody
(TPOAb) negativity was observed [21]. In turn, higher
TSH level and TPOAb positivity were independently
associated with lower chance of reversion to euthyroid-
ism [21]. Moreover, TSH levels ≥ 10 mIU/l were inde-
pendently associated with progression to overt
hypothyroidism [21]. Similar findings, showing that
higher baseline TSH levels are associated with progres-
sion from subclinical to overt hypothyroidism and that
higher TSH level (> 8 mIU/l) is a predictive value for de-
velopment of overt hypothyroidism, were recently
reported by Imaizumi et al. [22]. On the other hand,
there is strong evidence that thyroid hypofunction may
contribute to increased lifespan (see further in the text).
Therefore, taking into account all mentioned observa-
tions, the replacement therapy with L-thyroxine is not
uniformly recommended in elderly people with subclin-
ical hypothyroidism.
In turn, subclinical hyperthyroidism, characterized by
serum TSH levels below lower limit of the reference
range and normal serum FT4 levels, is observed in about
8% of individuals aged 65 years and older [23]. Subclin-
ical hyperthyroidism may be associated in older adults
with decreased bone mineral density and fractures [24],or cognitive impairment [23] (reviewed in [25]). Further-
more, subclinical hyperthyroidism is associated with
increased risk of total, as well as CHD mortality and
atrial fibrillation (AF) incidents [26]. The highest risks of
CHD mortality and AF are observed in the case of TSH
levels lower than 0.1 mIU/l [26]. Unexpectedly, de Jongh
et al. [15] have reported that subclinical hyperthyroidism
is not associated with impairment of physical and cogni-
tive function or depression in elderly people, aged
65 years and older. These authors have also demon-
strated that subclinical hyperthyroidism is not associated
with the increased overall mortality risk [15]. Such
results are quite difficult to explain. Presumably, that
ambiguity in observations may result from differences
in the number of individuals enrolled in particular
studies or from follow-up duration. Interestingly, Rosario
[27] has recently shown that progression of subclinical
hyperthyroidism to overt hyperthyroidism in elderly
patients is an uncommon observation. Nevertheless,
since subclinical hyperthyroidism (and obviously, overt
hyperthyroidism with increased T4 level) may lead to
increased risk of total, as well as CHD mortality, patients
older than 65 years, with low TSH levels – particularly in
case of toxic multinodular goitre or a solitary autono-
mous thyroid nodule – require proper medical treatment
(e.g. [11]).
It should also be stressed that during aging, gender-
specific alterations in TSH and free thyroid hormone
levels were observed [28]. Namely, with increasing age
in males there were decreases in free thyroid hormones
but not in TSH concentrations. In turn, in females, the
free thyroid hormone levels were not changed with aging
but TSH level increased in age-dependent manner [28].
Most recent results indicate that even in euthyroid
older men with normal levels of TSH, differences in FT4
levels within the normal range predict specific health
outcomes relevant to aging. For example, higher FT4
within the normal range was independently associated
with frailty in euthyroid men aged ≥70 years [12]. More-
over, higher FT4 levels within the normal range were
associated with lower hip bone mineral density, increas-
ing bone loss and fracture risk in postmenopausal
women [29]. Therefore, it seems that further studies are
required to explain whether higher FT4 levels contribute
causally (or not) to the above mentioned poorer health
outcomes. Moreover, it is of interest to clarify whether
FT4 levels in the low-normal range could be considered
as potential biomarkers for healthy aging [12].
Although numerous studies demonstrate that the
increased TSH level resulting from subclinical
hypothyroidism further rises with aging [6-12], other
findings suggest that aging is associated – in the absence
of any thyroid disease – with lower TSH levels [30-35].
It has been known that TSH secretion in response to
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aging individuals, and serum TSH level is usually lower
in older than in young people in response to decreased
thyroid hormone concentrations, suggesting a certain
level of insensitivity of thyrotrophic cells in anterior pi-
tuitary, occurring with age; moreover, nocturnal surge
of TSH is – to various degree – lost in the elderly
(reviewed in [1]). On the other hand, Bremner et al.
[10] have recently reported that the TSH increase –
observed by other authors during aging – seems to be
a consequence of age-related alteration in the TSH set
point or reduced TSH bioactivity. Interestingly, the lar-
gest TSH increase is observed in people with the lowest
TSH at baseline, and, in turn, people with higher base-
line TSH levels had proportionally smaller increases in
TSH concentrations [10]. It is worth adding that TRH
and FT4 serum levels do not differ between young,
middle-aged and elderly subjects [34].Thyroid dysfunction and longevity
As it has been mentioned above, the alterations in levels
of hormones related to pituitary-thyroid axis are asso-
ciated with the process of aging and, thus, may impact
longevity. However, a direction of these changes, which
may lead to increased lifespan, still seems to be not fully
determined [6-12,30-35].
One should emphasize that the most striking findings
concerning potential contribution of TSH and thyroid
hormones to lifespan regulation, were obtained in the
studies performed on centenarians (and almost cente-
narians). In 2009, Atzmon et al. [7] published the results
of studies on thyroid disease-free population of Ashken-
azi Jews, characterized by exceptional longevity (cente-
narians). They have observed higher serum TSH level
in these subjects as compared to the control group
consisted of younger unrelated Ashkenazi Jews, as well
as to another control group obtained from The National
Health and Nutrition Examination Survey (NHANES)
program of studies [7]. Therefore, these findings appear
to support previous observations, indicating that serum
TSH shifts progressively to higher levels with age
(e.g., [36]). Moreover, the authors have observed an in-
verse correlation between FT4 and TSH levels in cente-
narians and Ashkenazi controls, and finally, they have
distinctly concluded that increased serum TSH is asso-
ciated with extreme longevity [7]. In another study, a
role of genetic background, potentially responsible for
the above-mentioned changes, was assessed [37]. It
turned out that two (2) single nucleotide polymorphisms
(SNPs) in TSH receptor (TSHR) gene, namely
rs10149689 and rs12050077, were associated with
increased TSH level in the Ashkenazi Jewish centenar-
ians and their offspring [37].The above-mentioned inverse correlation between FT4
and TSH in centenarians may suggest a potential role of
decreased thyroid function in lifespan regulation, leading
to remarkable longevity. Such a hypothesis seems to
have been confirmed by the findings obtained in the Lei-
den Longevity Study, demonstrating the associations be-
tween low thyroid activity and exceptional familial
longevity [38].
In turn, Corsonello et al. [39] have demonstrated that
age is associated with a decrease in free triiodothyronine
(FT3) and FT4 but not with increased TSH levels. More-
over, children and nieces/nephews of centenarians had
lower FT3, FT4 and TSH levels as compared to the age-
matched subjects [39]. It may, at least partially, confirm
an important role of low thyroid function in the regula-
tion of lifespan.
It should be stressed that reduced thyroid function
with low levels of T4 is associated with extended longev-
ity also in animals [40-42]. For example, a very severe
thyroid hypofunction with reduced core body
temperature, as observed in Ames dwarf (df/df ) and
Snell mice (characterized by mutations at the Prop-1
and Pit-1 gene, respectively, and demonstrating a lack of
growth hormone (GH), prolactin and TSH), is consid-
ered to substantially contribute to remarkable longevity
in these rodents [40]. Furthermore, severe hypothyroid
Ames dwarfs and mice with targeted disruption of the
growth hormone receptor/growth hormone binding pro-
tein gene (GH receptor knockout; GHRKO) with mild
thyroid hypofunction, have decreased thyroid follicle size
which may explain decreased thyroid hormone levels in
these mutants [43].
Concluding, the findings in animals are consistent
with the results obtained in humans and may confirm a
relevant role of thyroid hypofunction in lifespan
extension.
Thyroid cancerogenesis and aging processes
The prevalence of thyroid nodules and thyroid neo-
plasms is increased in the elderly. Among elderly people,
males are at higher risk of cancer and thyroid cancer is
more aggressive in men than in women [44].
Papillary thyroid carcinoma (PTC) is the most com-
mon endocrine malignant neoplasm in the older indivi-
duals. Women are affected by PTC two to three times
more often than men [45]. Nevertheless, female-to-male
ratio seems to decline with the process of aging [45]. Im-
portantly, the mortality rate of PTC is usually higher in
the elderly [46]. Presumably, it is a consequence of
increased mitotic activity of these tumors and increased
likelihood of distant metastases [46]. It is known that in
general population patients with aggressive variants of
PTC have higher risk for the metastatic disease develop-
ment [47]. The potential role of NDRG2 gene expression
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raised [48]. It is worth recalling that mutated BRAF gene
is an independent predicting factor of poor outcome in
PTC and is related to advanced age [49].
Follicular thyroid carcinoma (FTC) occurs also often
in older people and is the second most common and the
second least aggressive thyroid cancer. This cancer is
more likely to metastasize hematogenously to distant
sites, resulting in a worse prognosis in comparison with
PTC [44].
Medullary thyroid carcinoma (MTC), which derives
from the parafollicular cells (C cells) of the thyroid
gland, constitutes up to 5% of all thyroid malignancies.
Its sporadic form, more frequent than is familial MTC,
occurs more commonly in the older population [50].
Rapidly growing and typically very aggressive anaplas-
tic (undifferentiated) thyroid carcinoma (ATC) is rare.
However, one should strongly emphasize that its preva-
lence is considerably higher in older than in younger
people. By the time of diagnosis, most patients have
widespread local invasion and distant metastases. Age
appears to be a strong predictor of poor prognosis in
ATC [44].
Conclusions
The process of aging strongly affects entire endocrine
system. Consistently, thyroid gland is also impacted by
aging. One should emphasize that thyroid diseases-
associated symptoms in the elderly people are very similar
to symptoms of the normal aging. Therefore, broadening
the knowledge on alterations in thyroid function, which
may be observed during aging, appears to be very import-
ant and constitutes a challenge for thyroid researchers,
given that some specific thyroid dysfunctions may con-
tribute to lifespan extension.
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